3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Pancreatic Neoplasms
7
Colorectal Neoplasms
5
Breast Neoplasms
5
Prostatic Neoplasms
4
COVID-19
4
Neoplasms
3
Carcinoma, Non-Small-Cell Lung
3
Ovarian Neoplasms
2
Lung Neoplasms
2
Cholangiocarcinoma
2
Untreated Resectable Pancreatic Adenocarcinoma
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Rectal Neoplasms
1
Peripheral Nervous System Diseases
1
Pancreatic Cancer Resectable
1
Neoplasm, Residual
1
Liver Neoplasms
1
Leukemia, Myeloid, Chronic-Phase
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Leukemia
1
Klatskin Tumor
1
Hypoxia
1
Hematologic Neoplasms
1
Glioblastoma
1
Gastrointestinal Neoplasms
1
Colonic Neoplasms
1
Carcinoma, Transitional Cell
1
Biliary Tract Neoplasms
1
Interventions
nimotuzumab
1
avelumab
1
Hydroxychloroquine
1
Gemcitabine
1
130-nm albumin-bound paclitaxel
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Pancreatic Cancer Resectable
×
Hydroxychloroquine
×
Clear all
NCT03344172
2020-05-14
17-134
University of Pittsburgh
Phase 2
Terminated
32 enrolled
14 charts